Previous 10 | Next 10 |
home / stock / nvo / nvo articles
Retail investors are talking about a slim group of topics on Reddit this week including Novo Nordisk A/S (NYSE:NVO), weight-loss drug Ozempic and t...
Ross Gerber, a prominent Tesla investor, has suggested that using Ozempic could lead to significant cost savings. What Happened: Gerber took to X (...
In a move to demystify the conversation around obesity and weight management medications, Oprah Winfrey has taken to the airwaves with a prime-time...
Eli Lilly And Co’s (NYSE:LLY) much-in-demand weight-loss drug Zepbound (tirzepatide) surged ahead with 77,590 new prescriptions in the U...
As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medicat...
Tuesday, Fractyl Health Inc (NASDAQ:GUTS) released new preclinical findings for the first clinical candidate in its Rejuva pancreati...
The Centers for Medicare and Medicaid Services (CMS) is considering the inclusion of Novo Nordisk’s (NYSE:NVO) obesity drug Wegovy in its cov...
Future Fund co-founder Gary Black on Monday shared information about legendary television mogul Oprah Winfrey’s upcoming TV sp...
In response to growing reports of patient harm caused by counterfeit versions of its popular diabetes drug, Ozempic (semaglutide), Novo Nordis...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...